These findings suggest that somatic mutations in exon3 (if there are any) are also associated with decreased ZNF668 protein expression, while the factors responsible for the decreased ZNF668 protein expression in most bladder cancer cases may be mainly due to factors other than somatic mutations in the exon region such as mutations in regulatory regions or epigenetic changes. This evidence concerns the gene ZNF668 and urinary bladder cancer.